Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score.

Frost AE, Hoeper MM, Barberá JA, Vachiery JL, Blair C, Langley J, Rubin LJ.

J Heart Lung Transplant. 2018 Sep 9. pii: S1053-2498(18)31540-7. doi: 10.1016/j.healun.2018.07.001. [Epub ahead of print]

PMID:
30209017
2.

Clinical phenotypes and outcomes of pulmonary hypertension due to left heart disease: Role of the pre-capillary component.

Caravita S, Faini A, Carolino D'Araujo S, Dewachter C, Chomette L, Bondue A, Naeije R, Parati G, Vachiéry JL.

PLoS One. 2018 Jun 19;13(6):e0199164. doi: 10.1371/journal.pone.0199164. eCollection 2018.

3.

Correction to: Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.

Gall H, Vachiéry JL, Tanabe N, Halank M, Orozco-Levi M, Mielniczuk L, Chang M, Vogtländer K, Grünig E.

Lung. 2018 Jun;196(3):313. doi: 10.1007/s00408-018-0112-z.

PMID:
29616325
4.

Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.

Gall H, Vachiéry JL, Tanabe N, Halank M, Orozco-Levi M, Mielniczuk L, Chang M, Vogtländer K, Grünig E.

Lung. 2018 Jun;196(3):305-312. doi: 10.1007/s00408-018-0100-3. Epub 2018 Feb 22. Erratum in: Lung. 2018 Apr 3;:.

5.

Haemodynamics to predict outcome in pulmonary hypertension due to left heart disease: a meta-analysis.

Caravita S, Dewachter C, Soranna D, D'Araujo SC, Khaldi A, Zambon A, Parati G, Bondue A, Vachiéry JL.

Eur Respir J. 2018 Apr 4;51(4). pii: 1702427. doi: 10.1183/13993003.02427-2017. Print 2018 Apr. No abstract available.

PMID:
29439019
6.

Macitentan in pulmonary hypertension due to left ventricular dysfunction.

Vachiéry JL, Delcroix M, Al-Hiti H, Efficace M, Hutyra M, Lack G, Papadakis K, Rubin LJ.

Eur Respir J. 2018 Feb 7;51(2). pii: 1701886. doi: 10.1183/13993003.01886-2017. Print 2018 Feb.

PMID:
29437943
7.

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.

McLaughlin VV, Jansa P, Nielsen-Kudsk JE, Halank M, Simonneau G, Grünig E, Ulrich S, Rosenkranz S, Gómez Sánchez MA, Pulido T, Pepke-Zaba J, Barberá JA, Hoeper MM, Vachiéry JL, Lang I, Carvalho F, Meier C, Mueller K, Nikkho S, D'Armini AM.

BMC Pulm Med. 2017 Dec 28;17(1):216. doi: 10.1186/s12890-017-0563-7.

8.

Hemodynamic Phenotyping of Pulmonary Hypertension in Left Heart Failure.

Naeije R, Gerges M, Vachiery JL, Caravita S, Gerges C, Lang IM.

Circ Heart Fail. 2017 Sep;10(9). pii: e004082. doi: 10.1161/CIRCHEARTFAILURE.117.004082. Review.

PMID:
28912263
9.

Pulmonary hypertension and ventilation during exercise: Role of the pre-capillary component.

Caravita S, Faini A, Deboeck G, Bondue A, Naeije R, Parati G, Vachiéry JL.

J Heart Lung Transplant. 2017 Jul;36(7):754-762. doi: 10.1016/j.healun.2016.12.011. Epub 2016 Dec 23.

PMID:
28131663
10.

Treatment of pulmonary arterial hypertension in Eisenmenger syndrome: Practice makes (almost) perfect.

Vachiery JL.

J Heart Lung Transplant. 2017 Apr;36(4):376-377. doi: 10.1016/j.healun.2016.12.008. Epub 2016 Dec 23. No abstract available.

PMID:
28110830
11.

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.

Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin LJ; AMBITION investigators.

Ann Rheum Dis. 2017 Jul;76(7):1219-1227. doi: 10.1136/annrheumdis-2016-210236. Epub 2016 Dec 30.

12.

Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research.

Hoeper MM, Lam CSP, Vachiery JL, Bauersachs J, Gerges C, Lang IM, Bonderman D, Olsson KM, Gibbs JSR, Dorfmuller P, Guazzi M, Galiè N, Manes A, Handoko ML, Vonk-Noordegraaf A, Lankeit M, Konstantinides S, Wachter R, Opitz C, Rosenkranz S.

Eur Heart J. 2017 Oct 7;38(38):2869-2873. doi: 10.1093/eurheartj/ehw597. No abstract available.

PMID:
28011705
13.

Pulmonary hypertension: the importance of correctly diagnosing the cause.

Mehta S, Vachiéry JL.

Eur Respir Rev. 2016 Dec;25(142):372-380. doi: 10.1183/16000617.0104-2016. Review.

14.

Obstructive Ventilatory Disorder in Heart Failure-Caused by the Heart or the Lung?

Caravita S, Vachiéry JL.

Curr Heart Fail Rep. 2016 Dec;13(6):310-318. Review.

PMID:
27817003
15.

Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.

Hoeper MM, McLaughlin VV, Barberá JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rosenkranz S, Oudiz RJ, White RJ, Miller KL, Langley J, Harris JHN, Blair C, Rubin LJ, Vachiery JL.

Lancet Respir Med. 2016 Nov;4(11):894-901. doi: 10.1016/S2213-2600(16)30307-1. Epub 2016 Oct 11.

PMID:
27745818
16.

Does third generation left ventricular assist device alter heart failure-related microvascular dysfunction?

Esmaeilzadeh F, Dendievel R, Wauters A, Vachiery JL, Van Nooten G, Van De Borne P, Argacha JF.

Acta Cardiol. 2016 Aug;71(4):403-10. doi: 10.2143/AC.71.4.3159692. No abstract available.

PMID:
27594355
17.

Composite indices of upstream pulmonary vascular impedance and capacitance do not help in identifying patients who should undergo pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension.

Vanden Eynden F, Bol Alima M, Racape J, El Oumeiri B, Vachiéry JL, Van Nooten G.

Acta Cardiol. 2016 Jun;71(3):281-90. doi: 10.2143/AC.71.3.3152088. No abstract available.

PMID:
27594123
18.

Pulmonary arterial hypertension associated with a von Hippel-Lindau gene mutation.

Caravita S, Deboeck G, Vachiery JL, Naeije R.

J Heart Lung Transplant. 2016 Sep;35(9):1138-9. doi: 10.1016/j.healun.2016.07.002. Epub 2016 Jul 16. No abstract available.

PMID:
27578599
19.

Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study.

Vachiéry JL, Hoeper MM, Peacock AJ, Sitbon O, Cheli M, Church C, Olsson KM, Palazzini M, Waterhouse B, Langley J, Galié N.

J Heart Lung Transplant. 2017 Apr;36(4):399-406. doi: 10.1016/j.healun.2016.04.013. Epub 2016 May 6.

PMID:
27282418
20.

Bosentan reverses the hypoxia-induced downregulation of the bone morphogenetic protein signaling in pulmonary artery smooth muscle cells.

Maruyama H, Dewachter C, Sakai S, Belhaj A, Rondelet B, Remmelink M, Vachiéry JL, Naeije R, Dewachter L.

Life Sci. 2016 Aug 15;159:111-115. doi: 10.1016/j.lfs.2016.05.018. Epub 2016 May 14.

PMID:
27188586
21.

The linear relationship between systolic pulmonary artery pressure and mean pulmonary artery pressure is maintained regardless of autonomic or rhythm disturbances.

Vanden Eynden F, Racapé J, Vincent J, Vachiéry JL, Bové T, Van Nooten G.

Respir Res. 2016 Mar 31;17:33. doi: 10.1186/s12931-016-0350-7.

22.

Update in treatment options in pulmonary hypertension.

Kanwar MK, Thenappan T, Vachiéry JL.

J Heart Lung Transplant. 2016 Jun;35(6):695-703. doi: 10.1016/j.healun.2016.01.020. Epub 2016 Jan 15.

PMID:
26952200
23.

2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension.

Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M.

Rev Esp Cardiol (Engl Ed). 2016 Feb;69(2):177. doi: 10.1016/j.rec.2016.01.002. No abstract available.

PMID:
26837729
24.

[2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension].

Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M.

Kardiol Pol. 2015;73(12):1127-206. doi: 10.5603/KP.2015.0242. Polish. No abstract available.

25.

How to cope with a temporarily aborted transplant program: solutions for a prolonged waiting period.

Vanden Eynden F, Antoine M, El Oumeiri B, Chirade ML, Vachiéry JL, Van Nooten GJ.

Ann Transl Med. 2015 Nov;3(20):306. doi: 10.3978/j.issn.2305-5839.2015.11.30.

26.

Response to the letter "Pulmonary artery wedge pressure and exercise oscillatory ventilation in pre-capillary pulmonary hypertension".

Vicenzi M, Deboeck G, Faoro V, Vachiery JL, Naeije R.

Int J Cardiol. 2016 Feb 1;204:12. doi: 10.1016/j.ijcard.2015.11.140. Epub 2015 Nov 23. No abstract available.

PMID:
26655525
27.

Left ventricular heart failure and pulmonary hypertension.

Rosenkranz S, Gibbs JS, Wachter R, De Marco T, Vonk-Noordegraaf A, Vachiéry JL.

Eur Heart J. 2016 Mar 21;37(12):942-54. doi: 10.1093/eurheartj/ehv512. Epub 2015 Oct 27. Review.

28.

At high cardiac output, diesel exhaust exposure increases pulmonary vascular resistance and decreases distensibility of pulmonary resistive vessels.

Wauters A, Vicenzi M, De Becker B, Riga JP, Esmaeilzadeh F, Faoro V, Vachiéry JL, van de Borne P, Argacha JF.

Am J Physiol Heart Circ Physiol. 2015 Dec 15;309(12):H2137-44. doi: 10.1152/ajpheart.00149.2015. Epub 2015 Oct 23.

29.

Exercise oscillatory ventilation in heart failure and in pulmonary arterial hypertension.

Vicenzi M, Deboeck G, Faoro V, Loison J, Vachiery JL, Naeije R.

Int J Cardiol. 2016 Jan 1;202:736-40. doi: 10.1016/j.ijcard.2015.09.087. Epub 2015 Sep 26.

PMID:
26469553
30.

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M; ESC Scientific Document Group .

Eur Heart J. 2016 Jan 1;37(1):67-119. doi: 10.1093/eurheartj/ehv317. Epub 2015 Aug 29. No abstract available.

31.

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M.

Eur Respir J. 2015 Oct;46(4):903-75. doi: 10.1183/13993003.01032-2015. Epub 2015 Aug 29. Erratum in: Eur Respir J. 2015 Dec;46(6):1855-6.

32.

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.

Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators.

N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687.

33.

Navigating the uncharted waters of combination therapy in pulmonary arterial hypertension: COMPASS or dead-reckoning.

Vachiery JL, Rubin LJ.

Eur Respir J. 2015 Aug;46(2):297-8. doi: 10.1183/13993003.00907-2015. No abstract available.

34.

Sildenafil improves renal function in patients with pulmonary arterial hypertension.

Webb DJ, Vachiery JL, Hwang LJ, Maurey JO.

Br J Clin Pharmacol. 2015 Aug;80(2):235-41. doi: 10.1111/bcp.12616. Epub 2015 May 19.

35.

Controversies in pulmonary hypertension due to left heart disease.

Cheli M, Vachiery JL.

F1000Prime Rep. 2015 Jan 5;7:07. doi: 10.12703/P7-07. eCollection 2015. Review.

36.

[Pulmonary hypertension due to left heart diseases].

Vachiéry JL, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galiè N, Ghio S, Gibbs JS, Martinez F, Semigran M, Simonneau G, Wells A, Seeger W.

Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:130-41. Turkish.

37.

Endothelin-Bone morphogenetic protein type 2 receptor interaction induces pulmonary artery smooth muscle cell hyperplasia in pulmonary arterial hypertension.

Maruyama H, Dewachter C, Belhaj A, Rondelet B, Sakai S, Remmelink M, Vachiery JL, Naeije R, Dewachter L.

J Heart Lung Transplant. 2015 Mar;34(3):468-78. doi: 10.1016/j.healun.2014.09.011. Epub 2014 Sep 28.

PMID:
25447587
38.

Living with pulmonary hypertension: unique insights from an international ethnographic study.

Kingman M, Hinzmann B, Sweet O, Vachiéry JL.

BMJ Open. 2014 May 16;4(5):e004735. doi: 10.1136/bmjopen-2013-004735.

39.

Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: clinical associations.

Dhaun N, Vachiery JL, Benza RL, Naeije R, Hwang LJ, Liu X, Teal S, Webb DJ.

J Heart Lung Transplant. 2014 May;33(5):521-7. doi: 10.1016/j.healun.2014.01.853. Epub 2014 Jan 23.

PMID:
24656288
40.

Pulmonary hypertension in chronic lung diseases.

Seeger W, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galiè N, Ghio S, Gibbs S, Martinez FJ, Semigran MJ, Simonneau G, Wells AU, Vachiéry JL.

J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D109-16. doi: 10.1016/j.jacc.2013.10.036. Review.

41.

Pulmonary hypertension due to left heart diseases.

Vachiéry JL, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galiè N, Ghio S, Gibbs JS, Martinez F, Semigran M, Simonneau G, Wells A, Seeger W.

J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D100-8. doi: 10.1016/j.jacc.2013.10.033. Review.

42.

[Pulmonary hypertension in left heart disease: how to define it and how to manage it in 2013?].

Yerly P, Aebischer N, Prella M, Aubert JD, Nicod L, Vachiéry JL.

Rev Med Suisse. 2013 May 29;9(388):1160-4, 1166-7. French.

PMID:
23789186
43.

Physiological response to the 6-minute walk test in chronic heart failure patients versus healthy control subjects.

Deboeck G, Van Muylem A, Vachiéry JL, Naeije R.

Eur J Prev Cardiol. 2014 Aug;21(8):997-1003. doi: 10.1177/2047487313482283. Epub 2013 Mar 19.

PMID:
23513011
44.

Practical recommendations on the use of echocardiography to assess pulmonary arterial hypertension--a Belgian expert consensus endorsed by the Working Group on Non-Invasive Cardiac Imaging.

Lancellotti P, Budts W, De Wolf D, Voigt JU, Pasquet A, De Sutter J, Friart A, Huez S, Paelinck B, Vachiéry JL; Working Group on Non-Invasive Cardiac Imaging.

Acta Cardiol. 2013 Feb;68(1):59-69.

PMID:
23457911
45.

Exercise-induced pulmonary hypertension: physiological basis and methodological concerns.

Naeije R, Vanderpool R, Dhakal BP, Saggar R, Saggar R, Vachiery JL, Lewis GD.

Am J Respir Crit Care Med. 2013 Mar 15;187(6):576-83. doi: 10.1164/rccm.201211-2090CI. Epub 2013 Jan 24. Review.

46.

Worsening in oxygen saturation and exercise capacity predict adverse outcome in patients with Eisenmenger syndrome.

Van De Bruaene A, De Meester P, Voigt JU, Delcroix M, Pasquet A, De Backer J, De Pauw M, Naeije R, Vachiéry JL, Paelinck BP, Morissens M, Budts W.

Int J Cardiol. 2013 Sep 30;168(2):1386-92. doi: 10.1016/j.ijcard.2012.12.021. Epub 2013 Jan 5.

PMID:
23295038
47.

Challenges in the diagnosis and treatment of pulmonary arterial hypertension.

Vachiéry JL, Gaine S.

Eur Respir Rev. 2012 Dec 1;21(126):313-20. doi: 10.1183/09059180.00005412. Review.

48.

Echocardiography of pulmonary vascular function in asymptomatic carriers of BMPR2 mutations.

Pavelescu A, Vanderpool R, Vachiéry JL, Grunig E, Naeije R.

Eur Respir J. 2012 Nov;40(5):1287-9. doi: 10.1183/09031936.00021712. No abstract available.

49.

[Pulmonary hypertension: a rare cause of unexplained dyspnea].

Vachiéry JL.

Rev Med Brux. 2012 Sep;33(4):280-2. Review. French.

PMID:
23091932
50.

Echocardiography in pulmonary arterial hypertension.

Forfia PR, Vachiéry JL.

Am J Cardiol. 2012 Sep 15;110(6 Suppl):16S-24S. doi: 10.1016/j.amjcard.2012.06.012. Review.

PMID:
22921027

Supplemental Content

Loading ...
Support Center